lpm3480226
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 18, 2018 (NCT03844438)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Indoleamine 2,3-dioxygenaseINHIBITOR
IDO1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03844438 | Phase 1 | Dec 18, 2018 | Luye Pharma, Nanjing Bangnuo Biotechnology Co. Ltd |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Luye Pharma | For profit | 1 | 1 | 1 | 2018 |
| Nanjing Bangnuo Biotechnology Co. Ltd | For profit | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1